Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06975059

Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients

Gait changes in Parkinson's disease are complex, variable, and difficult to detect during short clinic assessments. The aim of this study is to collect gait measurements in Parkinson's patients through sensors in a novel shoe device, NUSHU by Magnes AG. The shoe additionally provides vibrational feedback that can potentially help gait difficulties experienced by Parkinson's patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Parkinson's Disease (PD)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Parkinson's Disease:

Inclusion criteria

  • Male or female ≥ 18 years of age.
  • A diagnosis of Parkinson's disease
  • Able to give written informed consent (as determined by the investigator)
  • Can converse in English and read and perform all study activities
  • Has willingness and ability to comply with study requirements

Exclusion criteria

  • Diagnosis of an atypical parkinsonism syndrome, drug-induced parkinsonism, essential tremor, or other diagnoses that explain movement symptoms other than PD
  • A diagnosis of significant CNS disease other than PD such as stroke, multiple sclerosis, epilepsy
  • Persons with disorders other than PD significantly affecting gait as determined by the investigator
  • History of MRI brain scan indicative of clinically significant abnormality as determined by the investigator
  • Inability to wear interventional device
  • Unable to ambulate independently at least with assistive walking device but without additional person assistance
  • Pregnant or planning pregnancy within study timeframe
  • Montreal Cognitive Assessment (MoCA) score < 22 at screening
  • Resides in a nursing home or assisted care facility

Healthy Controls:

Inclusion criteria

  • Male or female ≥ 18 years of age.
  • No neurological disease or other significant gait impairment as deemed by the study investigator

Treatment and study plan

NUSHU shoe

Device

The NUSHU shoe, created by Magnes AG, can measure real-time detection of gait analysis while providing vibrotactile stimulus to the study participant through machine learning sensors. This may provide a feedback mechanism that acts as therapy for gait difficulties.

Primary outcomes

  1. Mean Score of Comfort Level of Device in Satisfaction Survey

    Time frame: At Safety Follow Up (Week 18)

    The satisfaction survey contains 2 demographic questions and 5 questions about participant satisfaction completed at end of study participation. The comfort level of the device question is the following: How would you rate the comfort level of the device? The scale is 0, 1, 2, 3, 4, 5, with 0 meaning most uncomfortable and 5 meaning most comfortable. Mean score for each individual question will be provided.

  2. Mean Score of Ease of Using Device in Satisfaction Survey

    Time frame: At Safety Follow Up (Week 18)

    The satisfaction survey contains 2 demographic questions and 5 questions about participant satisfaction completed at end of study participation. The comfort level of the device question is the following: How easy was it to use the device? The scale is 0, 1, 2, 3, 4, 5, with 0 meaning very easy and 5 meaning very difficult. Mean score for each individual question will be provided.

  3. Ratio of Participants Who Completed Study to Total Number of Participants Enrolled

    Time frame: Through study completion, 18 weeks

    We would like to measure the retention rate to assess feasibility. The lowest ratio would be 0, and the highest ratio would be 1.

Secondary outcomes

  1. Mean Change from Baseline to Week 12 in TUG test

    Time frame: At Baseline and In 12 Weeks

    Timed Up and Go test assesses mobility, balance, walking ability, and fall risk in older adults by measuring how quickly the patient can stand up, walk 10 feet, turn around, walk back, and sit down. The score is the amount of time taken in seconds. There is no highest nor lowest score. The higher the time, the more problems the patient has with gait and requires gait aid.

  2. Mean Change from Baseline to Week 12 in FOG Questionnaire

    Time frame: At Baseline and In 12 Weeks

    Freezing of Gait questionnaire assesses FOG severity unrelated to falls, FOG frequency, gait disturbances, and relationship to clinical features associated with gait and motor aspects in Parkinson's patients. The score ranges from 0 to 24, and high scores correspond to more severe FOG.

  3. Mean Change from Baseline to Week 12 in MDS-UPDRS III

    Time frame: At Baseline and In 12 Weeks

    The Movement Disorder Society (MDS)-Unified Parkinson's Disease Rating Scale (UPDRS) Part III (motor examination; to be completed in the on-medication state) has instructions for the rater to give or demonstrate to the participant; it is completed by the investigator. Each question has a 0-4 rating scale. The total scores range from 0 to 132, with higher scores indicate increased severity.

  4. Mean Change from Baseline to Week 12 in Stride Time

    Time frame: At Baseline and In 12 Weeks

    The NUSHU shoe measures the stride time: the time elapsed between the first contact of two consecutive footsteps of the same foot. This time is collected in seconds.

  5. Mean Change from Baseline to Week 12 in Stride Length

    Time frame: At Baseline and In 12 Weeks

    The NUSHU shoe measures the stride length: the distance covered between the same spot where one foot hits the ground and the next time the same foot hits the ground again. This distance is collected in meters.

  6. Mean Change from Baseline to Week 12 in Swing Time

    Time frame: At Baseline and In 12 Weeks

    The NUSHU shoes measure the swing time: the amount of time the foot spends off the ground in the gait cycle, defined by the time from toe off to heel strike of the same foot. The time is collected in seconds.

  7. Mean Change from Baseline to Week 12 in Stance Time

    Time frame: At Baseline and In 12 Weeks

    The NUSHU shoes measure the stance time: the duration of the time between heel strike and toe off of the same foot. This time is collected in seconds.

  8. Mean Change from Baseline to Week 12 in Velocity

    Time frame: At Baseline and In 12 Weeks

    The NUSHU shoes measure the velocity: mean in-plane velocity of each gait cycle (m/s).

  9. Mean Change from Baseline to Week 12 in Cadence

    Time frame: At Baseline and In 12 Weeks

    The NUSHU shoes measure the cadence: number of strides per minute.

  10. Mean Change from Baseline to Week 12 in Swing Phase

    Time frame: At Baseline and In 12 Weeks

    The NUSHU Shoes measure the swing phase: ratio of swing time with respect to gait cycle duration.

  11. Mean Change from Baseline to Week 12 in Stance Phase

    Time frame: At Baseline and In 12 Weeks

    The NUSHU shoes measure the stance phase: ratio of stance time with respect to gait cycle duration.

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Research Coordinator

CONTACT

[email protected]

Harini Sarva, MD

CONTACT

[email protected]

212-746-1685

Sponsors and collaborators

Lead sponsor

Weill Medical College of Cornell University

Other

Registry information

Official study title

Using the NUSHU Shoe to Analyze Gait Balance and Vibrotactile Feedback in Early, Moderate and Advanced PD Patients and Healthy Controls

Important dates

Study start
2025
Primary completion
2027
Study completion
2030
First posted
May 16, 2025
Registry last updated
Oct 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.